Efficacy News and Research

RSS

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

LEO Pharma A/S announces regulatory submission of ENSTILAR® for psoriasis in Europe

ENSTILAR® has the potential to be the first cutaneous foam approved for the treatment of psoriasis vulgaris.

26 Mar 2015

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

After six years of painstaking research, a UCLA-led team has validated the first standardized protocol for measuring one of the earliest signs of Alzheimer's disease -- the atrophy of the part of the brain known as the hippocampus.

26 Mar 2015

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

AdverseEvents Inc., a leading healthcare informatics company, today launched RxCost, the first methodology to identify the total costs of adverse drug reactions (ADRs) associated with FDA-approved drugs.

26 Mar 2015

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Arno Therapeutics, Inc., a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models.

26 Mar 2015

Alternating sunitinib, everolimus not supported in advanced RCC

Australian researchers report that an alternating regimen of sunitinib and everolimus, although feasible and low-risk in patients with advanced renal cell carcinoma, failed to meet the prespecified criteria for use or continued development.

25 Mar 2015

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

TVA Medical, Inc., today announced promising results from a clinical study evaluating a novel hemodialysis access technique that has the potential to revolutionize vascular access for patients with chronic kidney disease without the use of traditional open surgery.

25 Mar 2015

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed.

25 Mar 2015

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that it has initiated a Phase 2 trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer (TNBC) at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, China.

25 Mar 2015

Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

HAIR loss is one of the most distressing side-effects of cancer treatment and can even deter some patients from undergoing life-saving chemotherapy. But researchers at the University of Huddersfield are establishing the scientific basis for a rapidly-advancing scalp cooling technology that can ensure hair retention in a vast number of cases.

From Paxman 25 Mar 2015

Sympathetic nerve block shows no major benefit for PTSD in randomized controlled trial

A sympathetic nerve block that has shown promise for treatment of post-traumatic stress disorder (PTSD) performed no better than sham treatment in a randomized controlled trial, new research shows.

25 Mar 2015

Experimental drug that attacks brain tumor cells passes early tests

An experimental drug that attacks brain tumor tissue by crippling the cells' energy source called the mitochondria has passed early tests in animal models and human tissue cultures, say Houston Methodist scientists.

25 Mar 2015

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Primary ciliary dyskinesia (PCD) is a rare, genetic respiratory tract disorder leading to progressive pulmonary dysfunction. It exhibits many problems typical for orphan diseases: delayed diagnosis, limited evidence-based knowledge etc. The European Union is funding BESTCILIA (Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia) to introduce uniform guidelines for PCD treatment and diagnosis across Europe.

25 Mar 2015

New semi-transparent patch delivers effective treatment for tinnitus

Sufferers of tinnitus - an uncontrollable ringing in the ears - are getting some golden silence as Swedish scientists reveal a new treatment for the condition.

24 Mar 2015

Study explains why COPD patients develop tolerance to roflumilast drug

Roflumilast, a drug recently approved in the United States to treat severe chronic obstructive pulmonary disease (COPD), increases the production of a protein that causes inflammation, which possibly results in patients developing a tolerance to the drug after repeated use and makes the drug less effective, according to researchers at Georgia State University, Kumamoto University and the University of Rochester Medical Center.

24 Mar 2015

Mast plans to develop vepoloxamer for chronic heart failure treatment

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.

23 Mar 2015

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Efficacy News and Research

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

LEO Pharma A/S announces regulatory submission of ENSTILAR® for psoriasis in Europe

UCLA-led team validates first standardized protocol for tracking early signs of Alzheimer's disease

AdverseEvents launches RxCost to determine economic impact of prescribing particular drugs

Arno Therapeutics' AR-42 with cisplatin demonstrates anti-tumor effect in bladder cancer models

Alternating sunitinib, everolimus not supported in advanced RCC

TVA Medical's novel hemodialysis access technique shows positive outcomes in clinical study

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Scientists establish scientific basis for scalp cooling that can ensure hair retention after cancer treatment

Sympathetic nerve block shows no major benefit for PTSD in randomized controlled trial

Experimental drug that attacks brain tumor cells passes early tests

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

New semi-transparent patch delivers effective treatment for tinnitus

Study explains why COPD patients develop tolerance to roflumilast drug

Mast plans to develop vepoloxamer for chronic heart failure treatment

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News